Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1623526 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $30.04Day +1.90%Mkt cap $1.8B1Y +133.4%Off 52W high −25.3%Vol (1Y) 64.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,783 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest25.2% of sh out |
| Days to cover20.7d |
| 13F net flow (QoQ)+5.41% |
| Top-10 13F concentration57.5% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$32.1M |
| Earnings (TTM)-$169.8M |
| ROE−2.4% |
| Net margin−3.7% |
| Sales growth 3Y145.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−5.4% |
| 1Y+133.4% |
| 3Y+352.4% |
| 5Y+4.9% |
| Since incept. (ann.)+2.3% |
Total return through 2026-07-30 · series begins 2019-06-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)64.1% |
| Ann. volatility (3Y)81.3% |
| Sharpe (1Y)1.71 |
| Sharpe (3Y)1.00 |
| Max drawdown (1Y)−37.2% |
| Max drawdown (3Y)−66.3% |
| Beta (3Y vs SPY)2.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 5.6M | $183M | 9.51% | +1.4% |
| BlackRock, Inc. | 5.4M | $175M | 9.11% | +3.3% |
| FMR LLC | 5.4M | $175M | 9.10% | −3.9% |
| Lynx1 Capital Management LP | 4.8M | $155M | 8.05% | −11.9% |
| Redmile Group, LLC | 4.2M | $136M | 7.04% | +3.2% |
| MORGAN STANLEY | 3.4M | $111M | 5.79% | −3.5% |
| BAKER BROS. ADVISORS LP | 3.3M | $109M | 5.64% | +0.0% |
| TORONTO DOMINION BANK | 3.2M | $103M | 5.36% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 120.2% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 13,026,590 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.79 | −141.6% | $6.2M | −96.1% |
| 2025-12-31 | 2026-01-12 | — | — | $1.4M | −93.8% |
| 2025-09-30 | 2025-11-04 | −$0.65 | — | $10.6M | +117.2% |
| 2025-06-30 | 2025-08-12 | −$0.40 | — | $13.8M | +186.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
